Chunlin Chen This is Me

Education

 Web References

1. 1. pubs.acs.org

   pubs.acs.org/cen/coverstory/85 - [Cached]

   Last Visited: 12/6/2007

   Chunlin Chen, president and chief executive officer of the contract research company Medicilon, says a research dollar spent in Shanghai can stretch several times further than it would in the U.S.
   
   His firm, a provider of chemistry and biology research services, performs work on behalf of a growing number of customers ranging from multinational companies to U.S.-based university professors. Formed in 2004, the company is growing so fast that it's constantly looking for new space in which to expand, Chen notes. It recently secured a large plot of land in Zhejiang to provide roaming space for the primates it needs for its preclinical studies.
   
   Chen knows the steps involved in drug discovery. The holder of a Ph.D. in pharmacology and toxicology from Oklahoma State University, he worked at the U.S. drug discovery firm Vertex Pharmaceuticals as a team leader for preclinical drug evaluation. In collaboration with other team leaders, he managed the development of an Aurora kinase inhibitor, VX-680, that Vertex eventually sold to Merck for a total of $384 million. Another drug, the hepatitis C drug VX-350, is undergoing clinical trials. Before joining Vertex, Chen did research on drug discovery and development for six years at Parker Hughes Institute in Minneapolis-St. Paul, Minn.
   
   Jean-Fran,ois Tremblay/C&EN Mao
   
   While at Vertex, Chen noticed that U.S. companies were outsourcing more and more chemistry work to firms in China.
   ...
   Chen says companies that rely on lab animals in China are rigorously inspected by a wide range of officials. The death of primates, in particular, must be extensively explained in filed documents, he says.
   
   Some contract research firms pursue their own independent efforts to discover new drugs. But Medicilon does not intend to go down that route, Chen says, explaining that it's clearly a conflict of interest with the client's.

2. 2. acsinfo.acs.org

   acsinfo.acs.org/cen/coverstory - [Cached]

   Last Visited: 8/7/2007

   Chunlin Chen, president and chief executive officer of the contract research company Medicilon, says a research dollar spent in Shanghai can stretch several times further than it would in the U.S.
   
   His firm, a provider of chemistry and biology research services, performs work on behalf of a growing number of customers ranging from multinational companies to U.S.-based university professors. Formed in 2004, the company is growing so fast that it's constantly looking for new space in which to expand, Chen notes. It recently secured a large plot of land in Zhejiang to provide roaming space for the primates it needs for its preclinical studies.
   
   Chen knows the steps involved in drug discovery. The holder of a Ph.D. in pharmacology and toxicology from Oklahoma State University, he worked at the U.S. drug discovery firm Vertex Pharmaceuticals as a team leader for preclinical drug evaluation. In collaboration with other team leaders, he managed the development of an Aurora kinase inhibitor, VX-680, that Vertex eventually sold to Merck for a total of $384 million. Another drug, the hepatitis C drug VX-350, is undergoing clinical trials. Before joining Vertex, Chen did research on drug discovery and development for six years at Parker Hughes Institute in Minneapolis-St. Paul, Minn.
   
   Jean-Fran,ois Tremblay/C&EN Mao
   
   While at Vertex, Chen noticed that U.S. companies were outsourcing more and more chemistry work to firms in China.
   ...
   Chen says companies that rely on lab animals in China are rigorously inspected by a wide range of officials. The death of primates, in particular, must be extensively explained in filed documents, he says.
   
   Some contract research firms pursue their own independent efforts to discover new drugs. But Medicilon does not intend to go down that route, Chen says, explaining that it's clearly a conflict of interest with the client's.

3. 3. pubs.acs.org

   pubs.acs.org/cen/coverstory/85 - [Cached]

   Last Visited: 9/4/2007

   Chunlin Chen, president and chief executive officer of the contract research company Medicilon, says a research dollar spent in Shanghai can stretch several times further than it would in the U.S.
   
   His firm, a provider of chemistry and biology research services, performs work on behalf of a growing number of customers ranging from multinational companies to U.S.-based university professors. Formed in 2004, the company is growing so fast that it's constantly looking for new space in which to expand, Chen notes. It recently secured a large plot of land in Zhejiang to provide roaming space for the primates it needs for its preclinical studies.
   
   Chen knows the steps involved in drug discovery. The holder of a Ph.D. in pharmacology and toxicology from Oklahoma State University, he worked at the U.S. drug discovery firm Vertex Pharmaceuticals as a team leader for preclinical drug evaluation. In collaboration with other team leaders, he managed the development of an Aurora kinase inhibitor, VX-680, that Vertex eventually sold to Merck for a total of $384 million. Another drug, the hepatitis C drug VX-350, is undergoing clinical trials. Before joining Vertex, Chen did research on drug discovery and development for six years at Parker Hughes Institute in Minneapolis-St. Paul, Minn.
   
   Jean-Fran,ois Tremblay/C&EN Mao
   
   While at Vertex, Chen noticed that U.S. companies were outsourcing more and more chemistry work to firms in China.
   ...
   Chen says companies that rely on lab animals in China are rigorously inspected by a wide range of officials. The death of primates, in particular, must be extensively explained in filed documents, he says.
   
   Some contract research firms pursue their own independent efforts to discover new drugs. But Medicilon does not intend to go down that route, Chen says, explaining that it's clearly a conflict of interest with the client's.